Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

Eurolab has achieved a landmark legal victory in South Africa, allowing the company to produce and sell a generic version of ...

The matter arose after Eurolab identified the potential of enzalutamide, an inhibitor, used in the treatment of prostate ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

Astellas signed a memorandum of agreement with Yaskawa in May 2024. Credit: yu_photo/Shutterstock. Astellas Pharma and the ...

Astellas and Yaskawa are establishing a joint venture for the development of a cell therapy product manufacturing platform utilizing robotics.

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a ...

Eurolab granted right to sell generic prostate cancer treatment at an affordable price for South African patients.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and YASKAWA Electric Corporation (TSE: 6506, President and CEO; Masahiro Ogawa, "YASKAWA") signed a definitive agreement ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...